

Cell-free DNA has potential as a low-invasive diagnostic marker for early endometriosis

Anais Alonso^{1,2}, Nicole Yuwono^{1,3}, Sahar Houshdaran⁴, Jason Abbott^{1,2}, Caroline Ford^{1,3}, Kristina Warton^{1,3}

Background


A **non- or low-invasive diagnostic test** would decrease the substantial **diagnostic delay** currently reported for endometriosis.¹

One small retrospective study has suggested that **cell-free DNA (cfDNA)** is **elevated** in the **plasma** of women with endometriosis.² Additionally, we propose **endometrial cfDNA** as a **novel biomarker**.

Aim

To evaluate **total and endometrial-derived cfDNA** as low-invasive biomarkers for endometriosis in women **with and without** laparoscopically-confirmed **endometriosis**.

Methodology



Results

28 women with endometriosis

10 (36%) Superficial endometriosis
18 (64%) Deep endometriosis

15 controls

8 (53%) Leiomyomata
6 (40%) Adenomyosis


1 (7%) Appendicitis
2 (13%) No pathology

Total cfDNA concentration

Control
2.24 ± 0.89 ng/mL

Endometriosis
2.56 ± 0.92 ng/mL

p=0.274




Endometrial cfDNA concentration

Control
0.25 ng/mL
(IQR 0.19-0.40)

Endometriosis
0.29 ng/mL
(IQR 0.20-0.43)

p=0.593



Conclusions

The quantification of plasma **endometrial cfDNA** is **feasible**. The **small sample size** and **population heterogeneity** may have contributed to the **negative findings**.

Next steps

Reinvestigation of **endometrial cfDNA** in a larger cohort consisting of women with **superficial endometriosis** and controls **without coexisting pelvic pathology**.

